Molnupiravir is the first COVID-19 drug authorised by the Drugs Controller General of India (DCGI) for the treatment of COVID-19 infection ...

The drug is touted as a game-changer in the fight against the pandemic, and a panel of experts of the US Food and Drug Administration (FDA)...

Natco has conducted Phase III trials of molnupiravir and submitted the trial results to the drug regulator this month. "We have submitted p...

The Hyderabad-based firm said the first dose under the phase-III trials was given to a patient in the city-based Yashoda Hospitals.

Natco Pharma on Friday said it has initiated phase-III clinical trials of Molnupiravir capsules to evaluate its efficacy in treating patien...

Pre-clinical (animal) studies have found that Molnupiravir has remarkably reduced SARS-CoV-2 load and was found to have completely suppress...

Lily has issued voluntary licenses for Barcitinib to six Indian drug makers besides Natco, these include- Sun Pharma, Cipla, Dr Reddy's, Lu...

As the threat of compulsory licence (CL) looms over big pharma in India, companies are rushing in to sign voluntary licensing agreements th...

In its application, Natco has cited the unmet medical needs due to the lack of supply and affordability in light of the grave and life-thre...

Roche said that the production process for this drug is “very complex” and the company will do everything to ensure an equitable distributi...

Making its case, Natco’s application said Olumiant is not manufactured in India — less than 9,000 tablets were imported in 2019 and 2020, a...

In a statement, the Hyderabad headquartered pharma company said Baricitinib in combination with Remdesivir is used for the treatment of Cov...

Molnupiravir was originally developed to treat influenza before US-based Merck initiated research to repurpose drug for use against SARS-Co...

The development comes close on the heels of findings announced by the researchers that Molnupiravir was found effective for treating the pa...

Natco’s recent diversification of its exports to markets like Brazil, Canada, China, is doing well and is expected to do so in future as we...

Natco had in December sought a waiver of the clinical trial requirement for the emergency use of baricitinib tablets in Covid-19 treatment,...

Natco has sought nod for the manufacture and marketing of baricitinib bulk drug and tablets in 1 to 4 mg versions in India. This move may t...